Aker BioMarine Q2 revenue rises 5% on krill oil demand

Aker BioMarine (AKBM) reported Q2 revenue of $57.9M, up 5% YoY but below the $60M consensus, and adjusted EBITDA fell 4% YoY to $12.9M (vs. $14M estimates). Human Health Ingredients revenue rose 17% YoY, but EBITDA margin slipped as sales/marketing spend increased. The company reiterated expectations for continued YoY growth and improved profits in Human Health Ingredients, while Consumer Health Products remains under pressure and AKBM is exploring strategic alternatives with a potential transaction targeted for 2026.

Analysis

The main read-through is not that growth disappeared, but that it is being bought with spend, which keeps this in the “show me” bucket rather than a clean compounding story. When a nutraceutical/ingredient business has to lean harder on sales and marketing to keep volumes moving, the market should assume lower incremental margins and a longer path to valuation rerating than the top-line print suggests.

The weaker consumer-facing channel is the more important signal: shelf-space loss in U.S. retail often lags the initial sales decline, so the damage can persist for several quarters even if management sounds constructive. That creates a second-order risk for inventory and promo pressure across adjacent wellness brands, while strategic buyers will likely demand cleaner earnings quality before paying up for a carve-out.

The strategic alternatives process is a potential catalyst, but it is a 2026 story, not a near-term fix. Until there is evidence that Human Health Ingredients can expand EBITDA margins without heavy reinvestment, the stock is likely to trade on earnings durability rather than optionality; the contrarian mistake would be assuming a sale process automatically creates value when it may simply formalize the current discount. A faster-than-expected recovery would require either a clear rebound in U.S. retail sell-through or a visible step-up in standalone margin conversion.

Key Decisions for Investors

• No immediate long: stay out of AKBM on this print and wait 1-2 quarters for proof that Human Health Ingredients margins stabilize; the current setup looks like revenue quality is improving faster than earnings quality.
• If you need a relative-value expression, favor a quality ingredients/platform name such as IFF over AKBM on a 6-12 month view: IFF has more diversified end-market exposure and less binary dependence on a 2026 transaction process.
• Set a catalyst alert on AKBM for either a) two consecutive quarters of Human Health Ingredients EBITDA margin expansion or b) a named strategic buyer; absent one of those, the equity is likely to remain rangebound and expensive on a forward-EBITDA basis.